Osteoarthritis and Bone Disorders News

Patients treated with levothroxine are more likely to experience a reduction in quadricep muscle mass, which may increase the risk for knee osteoarthritis, according to data published in Arthritis Research & Therapy.

Patients with knee osteoarthritis who experience sleep disturbances are more likely to experience catastrophizing and worsened knee pain, according to data published in Arthritis Care & Research.

CHICAGO — An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023.

Morning stiffness lasting longer than 60 minutes is frequent in patients with hand osteoarthritis, and is linked to greater pain, lower function and decreased quality of life, according to data published in Osteoarthritis and Cartilage.

EULAR has initiated a survey that will collect data directly from patients on the impact and outcomes of rheumatic and musculoskeletal diseases, according to a statement released during the EULAR 2023 Congress.

EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.

Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.

Researchers and CEOs alike presented data recently at a “Shark Tank”-like session with lawmakers on Capitol Hill to discuss, and seek federal funding for, potential therapies for osteoarthritis.

Postmenopausal women with osteoporosis who use denosumab as a first-line therapy have lowers risk for fractures compared with women who use alendronate, according to an industry press release.

The FDA granted orphan drug designation and rare pediatric disease designation for a therapy to treat a rare pediatric skeletal disorder, according to an industry press release.